This company has been acquired
Resumen de acción REUN
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Reunion Neuroscience Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.42 |
| 52 Week High | CA$9.44 |
| 52 Week Low | CA$0.83 |
| Beta | 4.21 |
| 1 Month Change | -2.07% |
| 3 Month Change | 40.59% |
| 1 Year Change | -72.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.48% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| REUN | CA Biotechs | Mercado CA | |
|---|---|---|---|
| 7D | -3.4% | 6.4% | -1.1% |
| 1Y | -73.0% | -39.4% | 4.9% |
Rentabilidad vs. Industria: REUN underperformed the Canadian Biotechs industry which returned 21.7% over the past year.
Rentabilidad vs. Mercado: REUN underperformed the Canadian Market which returned 1.9% over the past year.
Volatilidad de los precios
| REUN volatility | |
|---|---|
| REUN Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Precio estable de las acciones: REUN's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: REUN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 16 | Greg Mayes | reunionneuro.com |
Resumen de fundamentos de Reunion Neuroscience Inc.
| Estadísticas fundamentales de REUN | |
|---|---|
| Capitalización bursátil | CA$16.64m |
| Beneficios(TTM) | -CA$38.10m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está REUN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de REUN | |
|---|---|
| Ingresos | CA$0 |
| Coste de los ingresos | CA$0 |
| Beneficio bruto | CA$0 |
| Otros gastos | CA$38.10m |
| Beneficios | -CA$38.10m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.25 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado REUN a largo plazo?
Ver rendimiento histórico y comparativa